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Introduction
Rheumatoid arthritis (RA) is a significant, chronic disease
that afflicts 1% of the general population in most countries
[1]. Joint damage typically occurs before patients are diag-
nosed, and most of the joint destruction occurs within the
first 2 years of diagnosis [2]. Therapeutic drugs such as
sulfasalazine and methotrexate (MTX) only slow the pro-
gression of the disease, suggesting that these drugs fail to
adequately quell the underlying pathophysiology of RA [3].
Tumor necrosis factor alpha (TNF-α) is elevated in sera
and synovial fluid of patients with RA, suggesting that it
may play a role in the pathology of the disease [4]. Soluble
TNF-α receptor or neutralizing antibodies against TNF-α
have been shown to prevent collagen-induced arthritis in
mice [5,6]. Furthermore, a human TNF-α (hTNF-α) trans-
genic mouse (Tg197) develops a chronic, progressive pol-
yarthritis with histologic features in common with RA [7].
Weight loss and joint swelling in these mice are correlated
with expression of hTNF-α mRNA in the joints [7] and
hTNF-α concentrations in the serum [8,9]. Previously,
Keffer  et al. [7] showed that progression of disease in
these mice could be prevented by treatment with anti-
TNF-α monoclonal antibody (mAb). In this study, we uti-
lized the Tg197 mouse model to further assess whether
anti-TNF-α treatment can ameliorate established disease
in both young and aged mice.
Materials and methods
Tg197 mice and anti-TNF-α α mAb treatment
Heterozygous Tg197 transgenic mice, obtained from Dr
George Kollias (Hellenic Pasteur Institute, Athens,
Anti-TNF-α = anti-tumor necrosis factor alpha; ELISA = enzyme-linked immunosorbent assay; hTNF-α = human tumor necrosis factor alpha; IFN =
interferon; IL = interleukin; mAb = monoclonal antibody; mRNA = messenger ribonucleic acid; MTX = methotrexate; PCR = polymerase chain
reaction; RA = rheumatoid arthritis; TNF-α = tumor necrosis factor alpha.
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Abstract
Anti-tumor-necrosis-factor-α (TNF-α) monoclonal antibody was
used to treat Tg197 transgenic mice, which constitutively
produce human TNF-α (hTNF-α) and develop a progressive
polyarthritic disease. Treatment of both young (7- or 8-week-
old) and aged (27- or 28-week-old) mice commenced when at
least two limbs showed signs of moderate to severe arthritis.
The therapeutic efficacy of anti-TNF-α antibody was assessed
using various pathological indicators of disease progression.
The clinical severity of arthritis in Tg197 mice was significantly
reduced after anti-TNF-α treatment in comparison with saline-
treated mice and in comparison with baseline assessments in
both young and aged mice. The treatment with anti-TNF-α
prevented loss of body weight. Inflammatory pathways as
reflected by elevated circulating hTNF-α and local expression
of various proinflammatory mediators were all diminished by
anti-TNF-α treatment, confirming a critical role of hTNF-α in this
model of progressive polyarthritis. More importantly, the
amelioration of the disease was associated with reversal of
existing structural damage, including synovitis and periosteal
bone erosions evident on histology. Repair of cartilage was age
dependent: reversal of cartilage degradation after anti-TNF-α
treatment was observed in young mice but not in aged mice.
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Greece)  [7], were identified by PCR analysis using
primers to the 3′-modified hTNF-α gene. Two experi-
mental groups of 25 mice were used. ‘Young mice’
were enrolled into the study when they developed clini-
cal signs of arthritis at 7 or 8 weeks of age. A second
group of mice was maintained disease-free with
10 mg/kg of anti-TNF-α mAb weekly starting at 4 weeks
of age; when they reached 24 weeks of age, the treat-
ment was stopped and these ‘aged mice’ were allowed
to develop arthritis before they were enrolled into the
study. The enrollment criteria for both young and aged
mice required them to have a clinical score of at least 2
on two limbs. The experimental protocols were
approved by Centocor’s Institutional Animal Care and
Use Committee.
The murine anti-TNF-α mAb used in this study binds with
high affinity to hTNF-α and prevents binding to the TNF
receptor [10]. Anti-TNF-α mAb was administered by
intraperitoneal injection at 10 mg/kg weekly and the
animals in the control group received weekly injections of
saline.
Clinical scores
Clinical scores were based on a previously described
scoring system [11] modified as follows: 0 (normal), 1
(edema or distortion of paw or ankle joints), 2 (distortion of
paw and ankle joints), or 3 (ankylosis of wrist or ankle
joints). The sum of all four paws was scored weekly, with a
maximum possible score of 12 per mouse.
Histologic processing of joints
Specimens were processed and scored as described pre-
viously [12,13] and in the supplementary material.
ELISA assay
Serum samples were separated from whole blood, which
was collected by intracardiac puncture at baseline and at
3, 6, and 16 weeks post-treatment. Serum levels of
hTNF-α were determined by ELISA at a 1:2 dilution
according to the manufacturer’s instructions (Biosource
International, Camarillo, CA, USA).
RNA isolation and RNase protection assay
Samples were prepared as described in the Supplemen-
tary material and analyzed in an RNase protection assay
according to the manufacturer’s instructions (PharMingen,
San Diego, CA, USA).
Statistical analysis
All data are expressed as means ± standard deviation
unless noted otherwise. Statistical significance was tested
using analysis of variance for multiple groups. If significant
differences were found, pair-wise testing was performed
using Tukey’s test. The level of significance for all compar-
isons was set at P < 0.05.
Results
Amelioration of established polyarthritis by treatment
with anti-TNF-α α mAb
Increased cartilage turnover and repair in response to
insult has been observed in young mice, whereas aged
mice show decreased cartilage turnover after closure of
the growth plate [14]. Therefore, anti-TNF-α treatment
was evaluated in both young (7–8-week-old) and aged
(27–28-week-old) Tg197 mice with established arthritis.
The mean clinical arthritis score at baseline was 6 (Fig. 1),
indicating arthritis was established at the commencement
of treatment. The clinical arthritis score increased progres-
sively in the saline-treated group and these mice were
humanely killed at 6 weeks. In contrast, the clinical arthritic
score was markedly decreased in the groups, both young
and aged, treated with anti-TNF-α, indicating a marked
suppression of their arthritic symptoms (Fig. 1a,b). Mice in
the saline-treated group progressively lost weight,
whereas mice in the anti-TNF-α group showed a signifi-
cant weight gain throughout the study (see Supplemen-
tary Fig. 1). The arthritic score (weeks 1 to 16
post-treatment; Fig. 1a,b) and weight gain (weeks 5 to 16
post-treatment; Supplementary Fig. 1) in the group treated
with anti-TNF-α were significantly improved in comparison
with the saline-treated group in both young and aged
mice. More importantly, the arthritic scores for the group
treated with anti-TNF-α were significantly improved in
comparison with the baseline score from weeks 4 through
16 in both young and aged mice (Fig. 1a,b). These results
indicate that disease progression was not just prevented
but was reversed following anti-TNF-α treatment.
Effects of treatment with anti-TNF-α α mAb on joint
histopathology
All joints were scored in a blinded fashion for synovitis,
bone erosions, and cartilage degradation using a prede-
fined scoring system. The mean histologic scores for each
treatment group at various time points are shown in Fig. 2.
Saline treatment was followed by increased histologic
scores for synovitis, bone erosions, and cartilage damage
relative to that observed at baseline. Anti-TNF-α treatment
for 6 weeks significantly reduced all three histologic
scores relative to the baseline score in young mice (Fig. 2)
and two of the three histologic scores in aged mice (Sup-
plementary Fig. 2). After 16 weeks of anti-TNF-α treat-
ment, synovial inflammation and bone erosions were
almost completely resolved in both young and aged mice,
and a significant reduction in cartilage degradation in
comparison with baseline was maintained in young mice.
Cartilage degradation in aged mice treated with anti-
TNF-α was similar to that at the baseline measurement
and significantly lower than that in the saline treatment
group (Supplementary Fig. 2).
Representative tissue sections of the ankle joints from
young mice are shown in Fig. 3. Evidence of arthriticPage 3 of 7
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disease was readily observed at baseline (Fig. 3a,b), and
the disease continued to progress in saline-treated mice at
6 weeks, with increased cell proliferation and inflammatory
cell infiltration, erosion of cartilage and bone, and loss of
proteoglycan from the cartilage (Fig. 3c,d). However, after
6 weeks of anti-TNF-α treatment, improvements in all
histopathological parameters were observed with both
staining procedures (Fig. 3e,f). No visible evidence of bone
or cartilage erosion was observed and all signs of cellular
proliferation and infiltration disappeared. The proteoglycan
content of the cartilage was notably improved. Extended
treatment with anti-TNF-α (for 16 weeks) maintained
normal joint architecture (data not shown). These results
demonstrate that blocking hTNF-α reverses joint inflamma-
tion and promotes joint healing in this model of polyarthritis.
Inhibition of TNF-α α and other proinflammatory
cytokines
To define the underlying mechanisms by which anti-TNF-α
mAb ameliorated joint inflammation and structural damage,
the levels of various proinflammatory mediators were exam-
ined. First, circulating hTNF-α levels as detected by ELISA
were more than halved as early as 3 weeks and the reduc-
tion was sustained for 16 weeks after treatment with anti-
TNF-α mAb in comparison with saline-treated animals
(Fig. 4a). In addition, murine IL-6, IL-1β, and IFN-γ mRNA,
which are expressed in the arthritic joint tissues, were
clearly diminished following anti-TNF-α treatment when
total joint RNA was examined by RNase protection assays
(see Supplementary Fig. 3). When the levels of murine IL-6,
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Figure 1
Treatment with anti-TNF-α monoclonal antibodies reverses established
arthritis in Tg197 mice. (a) Young mice (at 7 to 8 weeks of age) or (b)
aged mice (at 27 to 28 weeks of age) with established arthritis were
randomized to three groups to be humanely killed immediately
(baseline, open square, n = 5) or to receive weekly doses of saline
(open circle, n = 10) or 10 mg/kg of anti-TNF-α (closed square, n =1 0
through 6 weeks of age and n = 5 from 7 to 16 weeks). The mice were
monitored weekly for arthritic score. *P < 0.05, versus saline-treated
controls; +P < 0.05, versus baseline score; both scores remaining
significant until the end of the study. Data are from two experiments.
TNF, tumor necrosis factor.
Figure 2
Synovitis, bone erosion, and cartilage degradation histology scores in
young Tg197 mice. Joint tissues were harvested at baseline (n = 5) and
after 6 weeks of saline treatment (n = 10) or 6 weeks (n = 5) or 16
weeks (n = 5) of treatment with anti-TNF-α monoclonal antibodies. All
paws were subjected to blinded histologic analysis. *P < 0.05, versus
baseline. mAb, monoclonal antibody; TNF, tumor necrosis factor.IL-1β, and IFN-γ mRNA were standardized to glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) (Fig. 4b–d), a
2–3-fold reduction in murine IL-6 and IFN-γ was observed
in the aged animals treated with anti-TNF-α in comparison
with those treated with saline at 6 weeks post-treatment
(Fig. 4b,c). Interestingly, local expression of murine TNF-α
mRNA was not affected by treatment with anti-TNF-α anti-
bodies, suggesting that hTNF-α plays a crucial role in the
pathogenesis of arthritis in this model.
Discussion
Currently, MTX is the most widely used disease-modifying
antirheumatic drug for the treatment of RA. However, MTX
treatment rarely results in complete disease remission [15]
and only slows the progression of joint erosion [16]. In
addition, long-term treatment with MTX is associated with
pulmonary [17] and liver toxicities [18] and other side
effects. Therefore, a treatment option that facilitates rever-
sal of joint damage and has longer effectiveness and
fewer side effects is desirable.
Experimental arthritis models have contributed to the basic
understanding of joint disease and to the development of
effective antiarthritic agents [19]. Several models have
been used to mimic human RA, ranging from immunization
with cartilage components to infection with joint trophic
organisms [20,21]. Blocking TNF-α [6,22] or IL-1 [23,24]
in these models has routinely shown benefit, although
some questions remain regarding the role of these
cytokines in mitigating joint inflammation versus preventing
cartilage degradation and bone erosion [25].
Using the Tg197 mice, we have shown that maintenance
anti-TNF-α therapy, initiated after joint inflammation and
erosions have occurred, allows damaged joints to heal.
Specifically, anti-TNF-α mAb proved equally effective in
reversing joint synovitis and erosions both in young mice,
where an active repair process to damage occurs, and
aged mice, where the repair process has relatively slowed.
However, the repair of cartilage damage was different
between young and aged mice. Cartilage in young mice
treated with anti-TNF-α was significantly improved relative
to saline-treated and baseline mice. By comparison, treat-
ment of aged mice with anti-TNF-α prevented further carti-
lage damage but did not improve histological scores
relative to baseline values. Mechanistically, the therapeutic
effect of anti-TNF-α appears to be due to either neutraliza-
tion of soluble hTNF-α or inhibition of hTNF-α production in
the diseased joint. Additionally, other proinflammatory
cytokine mRNAs were decreased in the local diseased
tissues either through suppression of inflammatory cell infil-
tration or inhibition of cytokine production. Moreover, anti-
TNF-α treatment resulted in a modest inhibition of murine
IL-1β production in the diseased joint, which is consistent
with previous findings that anti-TNF-α antibody inhibits the
generation of IL-1 in collagen-induced arthritis and IL-1, IL-
6, and IL-8 in rheumatoid synovial cultures [26,27]. Our
study provides preclinical evidence supporting the use of
anti-TNF-α mAb in ameliorating arthritic pathology.
The progressive arthritis observed in Tg197 mice is similar
to the pathology in patients with RA. Recent clinical data
indicate that the blockade of TNF-α significantly reduces
the signs and symptoms of RA [28,29] and inhibits the pro-
gression of structural damage [30,31]. It remains to be
seen whether extended anti-TNF-α therapy might permit
regeneration of articular cartilage and bone in established
human disease, where multiple etiological pathways may
contribute to the RA disease syndrome [32,33]. Neverthe-
less, it is likely that much of the RA pathology involves TNF-
α activation, and the results from the Tg197 model provide
a sound scientific rationale for the therapeutic benefits
observed following anti-TNF-α treatment in RA patients.
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Figure 3
Histology shows significant healing of arthritic joints in young Tg197
mice after treatment with anti-TNF-α mAb. Tissue sections of the ankle
joints were obtained from young Tg197 mice with established arthritis
at baseline (a,b) and after 6 weeks of treatment with saline (c,d) or
anti-TNF-α (e,f). Sections were stained with hematoxylin and eosin (a,
c, e) or toluidine blue (b, d, f). The arrows in panels (a) and (b) indicate
areas of cell infiltration (1), erosions (2) and loss of proteoglycan from
cartilage (3). Original magnification, 20×. mAb, monoclonal antibody;
TNF, tumor necrosis factor.Conclusion
Progression of established polyarthritis in the Tg197
hTNF-α transgenic mouse can be reversed by treatment
with anti-TNF-α mAb, as shown by significant improve-
ment in clinical and histological scores.
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Supplementary material
Supplementary materials and methods
Histologic processing of joints
Joint tissues from wrists, ankles, elbows, and knees were
fixed in 10% buffered formalin overnight, decalcified in
10% formic acid for 18 days, dehydrated, and then
embedded in paraffin. Specimens were cut longitudinally
to the midline, and 5-µm sections mounted for staining
with hematoxylin and eosin or toluidine blue. Joint sections
stained with hematoxylin and eosin were scored for syn-
ovitis and bone erosions, as described elsewhere [12,13].
Sections stained with toluidine blue were scored for carti-
lage degradation (0, normal staining; 1, some loss of stain-
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Supplementary Figure 1
Anti-TNF-α treatment reverses weight loss in arthritic animals. (a)
Young (at 7 to 8 weeks of age) or (b) aged mice (at 27 to 28 weeks of
age) with established arthritis (arthritic score of 2 in at least two limbs)
were randomized to three groups to be humanely killed immediately
(baseline, n = 5) or to receive weekly doses of saline (open circle,
n = 10) or 10 mg/kg of anti-TNF-α (closed square, n = 10 through
6 weeks and n = 5 from 7 to 16 weeks). Weight gain was measured
as change from pretreatment weight. *P < 0.05, versus saline controls,
and remained significant until the end of the study. TNF, tumor
necrosis factor.ing; 2, moderate loss of staining; 3, weak staining; 4, very
weak staining; 5, no visible staining). Specimens were
examined using light microscopy and scored in a blinded
fashion with regard to treatment.
RNA isolation and RNase protection assay
Excised ankle and paw joints were immediately frozen in
liquid nitrogen and processed in a freezer/mill (SPEX Certi-
Prep, Metuchen, NJ, USA) with liquid nitrogen at 2-minute
pulses. RNA was isolated from 50 mg of the joint powder
with 1 ml Trizol reagent according to the manufacturer’s
instructions  (Gibco BRL, Grand Island, NY, USA). RNA
was extracted with 0.2 ml chloroform, precipitated with
0.5 ml isopropyl alcohol, and resuspended in 30 µl diethyl
pyrocarbonate-treated water. Ten micrograms of total RNA
from each sample was used for RNase protection assay
(mCK –2b and –3b Multi-Probe Template Sets, PharMin-
gen, San Diego, CA, USA), exposed to a Phosphor screen,
and quantified by a Phosphorimager with the use of Image
Quant software (Molecular Dynamics, Sunnyvale, CA,
USA). The signal-intensity ratio of different cytokine mes-
senger RNA (mRNA) to GAPDH was determined.
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Supplementary Figure 2
Histology scores for synovitis, bone erosion, and cartilage degradation
in aged mice. Joint tissues were harvested at baseline (n = 5), after 6
weeks of saline treatment (n = 10), or after 6 weeks (n = 5) or 16
weeks (n = 5) of anti-TNF-α treatment. All paws were subjected to
blinded histologic analysis. *P < 0.05, versus baseline; +P < 0.05,
versus saline-treated controls. mAb, monoclonal antibody; TNF, tumor
necrosis factor.
Supplementary Figure 3
Detection of mRNA of proinflammatory cytokines murine TNF-α, IL-6,
and IFN-γ in joint tissue of aged mice. RNA was extracted from the
paw joints at baseline and after 6 weeks of treatment with saline or
anti-TNF-α. An RNase protection assay was then performed. GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; L32, ribosomal protein;
TNF, tumor necrosis factor.